Latest journal
All journals
October 2021
Axial spondyloarthritis (AxS) and psoriatic arthritis (PsA) are two types of chronic inflammatory disease presented with an array of unmet needs regarding their diagnosis and management. Presenting symptoms such as axial skeleton pain, enthesitis, and arthritis, patients with AxS and PsA commonly experience diagnostic delay, which hinders disease evaluation…
Latest articles
All articles
This CME-accredited presidential debate-style discussion explores the topic of biosimilars within rheumatology, der… twitter.com/i/web/status/1…
Posted 18 May
In this episode, we delve into some of the key insights provided by our guests, as well as other notable conversati… twitter.com/i/web/status/1…
Posted 26 April
We are pleased to announce @EMJReviews has been awarded the Queen’s Award for Enterprise for International Trade. F… twitter.com/i/web/status/1…
Posted 21 April
In this episode, Jonathan delves deeper into the history of battlefield medicine and how war can give rise to groun… twitter.com/i/web/status/1…
Posted 10 April
The challenges of the emergency in #Ukraine expose and exaggerate the difficulties faced by patients with rare dise… twitter.com/i/web/status/1…
Posted 30 March
Latest abstracts
All abstracts
Differences in Low-Density Lipoprotein Particle Composition and Oxidation May Underlie the Paradoxical Association of Low Levels with Higher Coronary Atherosclerosis Burden in Rheumatoid Arthritis
In fact, patients with RA in the lowest low-density lipoprotein (LDL) group (<70 mg/dL) may experience an unexpectedly high CVD risk.2 The authors explored whether patients with LDL 130 mg/dL), as a reason for this risk.
Read More

Association Between Environmental Air Pollution and Rheumatoid Arthritis Flares
Environmental air pollution has been linked to the pathogenesis of rheumatoid arthritis (RA).1 Nevertheless, there is no evidence linking higher concentrations of air pollutants with the risk of RA reactivations.
Read More

RESOLVE-1, a Phase III Trial of Lenabasum for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Lenabasum is an oral, non-immunosuppressive, cannabinoid Type 2 receptor agonist that activates resolution of innate immune responses.1 In animal models of bleomycin-induced skin and lung fibrosis, lenabasum reduced inflammation and fibrosis
Read More